Long-term Efficacy and Safety of HMS5552 in T2DM Subjects
Status:
Completed
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety and population PK of HMS5552 as monotherapy in
adult type 2 diabetic subjects, there will be 2 groups in the first 24 weeks, one group will
receive HMS5552 , while the other group will receive placebo ; after 24 weeks, all subjects
will receive HMS5552 for 28 weeks.